Check-Cap Reports Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

Check-Cap Ltd. (NASDAQ: CHEK) announced its Q4 and full-year 2021 financial results, revealing a net loss of $5.5 million for Q4 and $17.2 million for the full year. The company is advancing its C-Scan® test, aiming for a pivotal U.S. trial startup in April 2022. FDA approved an amended Investigational Device Exemption, facilitating this trial's initiation. Cash reserves stand at $51.9 million as of year-end 2021, bolstered by a $10 million offering in March 2022. Check-Cap believes it can sustain operations into Q1 2024, focusing on expanding colorectal cancer screening options.

Positive

• FDA approval of the amended Investigational Device Exemption, enabling U.S. pivotal study initiation.
• Sufficient cash reserves of $51.9 million as of December 31, 2021, projected to fund operations into Q1 2024.
• Recent $10 million registered direct offering enhances financial stability.
• Strengthening of clinical team with new appointments to support C-Scan development.

Negative

• Operating loss increased to $5.6 million in Q4 2021 from $3.9 million in Q4 2020.
• Net loss for the full year rose to $17.2 million from $13.8 million in 2020.
• Research and development expenses increased significantly, reflecting higher headcount and material costs.

Company anticipates initiation of the first part of its U.S. pivotal study in April 2022

ISFIYA, Israel, April 7, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results for the fourth quarter and full year ended December 31, 2021.

2021 and Recent Highlights:

Clinical Progress: In February 2022, the U.S. Food and Drug Administration (FDA) approved the Company's amended Investigational Device Exemption (IDE) application, enabling initiation of the U.S. pivotal study. The first part of the pivotal study will focus on device calibration and enhancement of C-Scan algorithms and is anticipated to begin in April 2022. The second part of the trial, anticipated to begin in Q4 2022, will compare performance of C-Scan to traditional colonoscopy. This second comparative portion of the study will be analyzed for statistical significance and will serve as the basis for the Company's filing of FDA approval in the U.S. The Company also continues patient enrollment and data collection at Israeli sites, to further enable optimization of C-Scan's functionality and patient experience in parallel to the U.S. pivotal trial.

Strengthened Manufacturing Capacity: In 2021, the Company expanded the C-Scan manufacturing capacity and on-premise production line to ensure optimized execution of the U.S. pivotal study.

Expanded Clinical Team: In 2021, the Company strengthened its clinical team with the appointment of Dr. Hanit Brenner-Lavie as vice president of Clinical Affairs and of additional qualified clinical employees. Dr. Brenner-Lavie is leading the Company's overall clinical strategy and its implementation, including the execution of the planned U.S. pivotal trial.

Strengthened the Balance Sheet: Cash and cash equivalents, restricted cash and short-term bank deposits as of December 31, 2021 were $51.9 million. In March 2022, the Company consummated a $10 million registered direct offering. The Company believes that it has sufficient capital to fund its ongoing operations and plans into the first quarter of 2024. 

Intellectual Property: In 2021, the Company was granted four new patents, including a new U.S. patent covering the C-Scan® proprietary tracking technology that enables real time tracking of the capsule and its activation only when it moves throughout the colon. This functionality allows for optimal scanning along the gastrointestinal (GI) tract while maintaining low energy consumption during the procedure. The patent also covers the capsule positioning data recording for the C-Scan analysis suite, which enables gastroenterologists to make a clinical decision and generate a report with their diagnosis and recommendations. This patent will expire in May 2034. Corresponding patents were issued in Japan and China and patents were approved for granting in Europe and Israel.

Breakthrough Device Designation: In early 2021, the FDA approved the Company's Breakthrough Device Designation, strengthening C-Scan's recognition as an alternative method to address the significant unmet need for patient-friendly CRC screening options.

Regulatory Renewals: In late 2021, the European Medical Device Regulation (MDR) issued a renewal of the Company's CE mark approval valid until December 1, 2026. This is a regulatory achievement for the Company, among the first medical device companies to comply with the strict requirements of this new advanced directive. The updated MDR CE approval not only permits Check-Cap to commercialize C-Scan in Europe but provides further external validation of the Company's quality systems. Additionally, the Company received renewal from the Israeli Ministry of Health, the Medical Device Division (AMAR) for marketing of C-Scan in Israel. While currently the Company remains focused primarily on the U.S. market, both renewals enable Check-Cap to continue to explore opportunities to launch C-Scan in multiple international markets.

"2021 was a productive year for Check-Cap as we made progress towards the initiation of the U.S. pivotal trial of C-Scan, including advancing the manufacturing process, optimizing our device, and expanding the clinical team in the past year," said Alex Ovadia, chief executive officer of Check-Cap. "C-Scan aims to address issues associated with low adherence to preventive screenings with colonoscopies. We look forward to advancing the U.S. pivotal trial imminently to continue gathering clinical evidence of the potential of C-Scan to detect polyps before they may turn into cancer, through a more-patient friendly option. We believe C-Scan has the potential to redefine colorectal cancer screening in the future and we are excited to potentially bringing this option to the millions of people worldwide."

Financial Results for the Fourth Quarter Ended December 31, 2021

Research and development expenses, net, were $4.1 million for the three months ended December 31, 2021 compared to $2.8 million for the same period in 2020. The increase is primarily due to (i) an increase of approximately $0.5 million in salary and related expenses, mainly as a result of the expansion in employee head count and currency exchange rate fluctuation, (ii) an increase of approximately $0.4 million in other research and development expenses including clinical expenses, (iii) a $0.4 million increase in material expenses, and (iv) an increase of approximately $0.1 million in share-based compensation. 

The increase in research and development expenses, net between 2021 and 2020 was offset in part by a $0.1 million grant from the Israel Innovation Authority (the "IIA").

General and administrative expenses were $1.5 million for the three months ended December 31, 2021, compared to $1.1 million for the same period in 2020. The increase is primarily due to a $0.2 million increase in other general expenses, mainly associated with directors' and officers' liability insurance, a $0.1 million increase in salaries and related expenses and a $0.1 million increase in professional services. 

Operating loss was $5.6 million for the three months ended December 31, 2021, compared to an operating loss of $3.9 million for the same period in 2020.

Net finance income was $101,000 for the three months ended December 31, 2021, compared to $24,000 for the same period in 2020. 

Net loss was $5.5 million for the three months ended December 31, 2021, compared to $3.9 million for the same period in 2020.

Cash and cash equivalents, restricted cash and short-term bank deposits as of December 31, 2021 were $51.9 million as compared to $18.1 million as of December 31, 2020. On March 3, 2022, the Company consummated a registered direct offering for the sale of 20,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to an aggregate of 15,000,000 of the Company's ordinary shares. The registered direct offering resulted in gross proceeds to the Company of $10.0 million or approximately $8.9 million net of offering expenses. The Company believes that it has sufficient capital to fund its ongoing operations and plans into the first quarter of 2024.

The number of outstanding ordinary shares as of December 31, 2021 was 96,411,949. As of April 6, 2022, the number of outstanding ordinary shares was 116,411,949.

Financial Results for the Twelve Months Ended December 31, 2021

Research and development expenses, net, were $12.3 million for the twelve months ended December 31, 2021, compared to $10.0 million for the same period in 2020. The increase in research and development, net expenses between 2021 and 2020 was primarily due to (i) an increase of approximately $1.3 million in salary and related expenses, mainly as a result of an expansion in employee head count and currency exchange rate fluctuation, (ii) a $1.2 million increase in material expenses, (iii) an increase of approximately $0.16 million in share-based compensation, and (iv) an increase of approximately $0.3 million in other research and development expenses including clinical expenses. The increase in research and development expenses, net between 2021 and 2020 was offset in part by a $0.17 million decrease in subcontractor and consultants and a $0.43 million grant from the IIA.

General and administrative expenses were $5.0 million for the twelve months ended December 31, 2021, compared to $3.9 million for the same period in 2020. The increase in general and administrative expenses is primarily due to a $0.3 million increase in salaries and related expenses, a $0.1 million increase in professional services expenses and a $0.7 million increase in other general expenses, mainly associated with directors' and officers' liability insurance, offset in part by a $0.1 million decrease in share-based compensation expenses.

Operating loss was $17.3 million for the twelve months ended December 31, 2021, compared to $13.9 million for the same period in 2020.

Finance income, net, was $119,000 for the twelve months ended December 31, 2021, compared to $86,000 for the same period in 2020.

Net loss was $17.2 million for the twelve months ended December 31, 2021, compared to $13.8 million for the same period in 2020.

Net cash used in operating activities was $16.3 million for the twelve months ended December 31, 2021, compared to $13.1 million for the same period in 2020.

A copy of the Company's annual report on Form 20-F for the year ended December 31, 2021 has been filed with the U.S. Securities and Exchange Commission at www.sec.gov and posted on the Company's investor relations website at http://ir.check-cap.com/home. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to Mira Rosenzweig, chief financial officer, at mira.rosenzweig@check-cap.com.

About Check-Cap

Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer and enable early intervention and cancer prevention. The Company's disruptive capsule-based screening technology aims to help millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. It requires no bowel preparation, allowing the patients to continue their daily routine with no interruption. C-Scan is not intended to replace colonoscopy. A positive C-Scan result should be followed by colonoscopy. C-Scan is an investigational device and is not available for sale in the United States.

Legal Notice Regarding Forward-Looking Statements

This press release contains "forward-looking statements" about the Company's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2021 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise

Investor Contacts

Irina Koffler 
LifeSci Advisors, LLC 
646.970.4681
ikoffler@lifesciadvisors.com

Meirav Gomeh-Bauer
LifeSci Advisors, LLC 
+972(0)-54-476-4979
Meirav@lifesciadvisors.com

Media Contact

Mónica Rouco Molina
Account Supervisor - Europe
LifeSci Communications
mroucomolina@lifescicomms.com

 

 

 

CHECK CAP LTD.
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands except share data)
		December 31,			December 31,
		2 0 2 1			2 0 2 0
Assets
Current assets
Cash and cash equivalents	$	26,457	$		7,703
Restricted cash		350			350
Short-term bank deposit		25,104			10,079
Prepaid expenses and other current assets		839			285
Total current assets		52,750			18,417
Non-current assets
Property and equipment, net		1,793			823
Operating leases		1,116			398
Total non-current assets		2,909			1,221
Total assets	$	55,659	$		19,638
Liabilities and shareholders' equity
Current liabilities
Accounts payable and accruals
Trade	$	1,050	$		862
Other		680			345
Employees and payroll accruals		1,961			1,510
Operating lease liabilities		350			264
Total current liabilities		4,041			2,981
Non-current liabilities
Royalties provision		132			154
Operating lease liabilities		795			125
Total non-current liabilities		927			279
Shareholders' equity
Share capital, Ordinary shares, 2.4 NIS par value (360,000,000 authorized shares as of December 31
31, 2021 and 2020; 96,411,949 and 46,239,183 shares issued and
outstanding as of December 31, 2021 and 2020, respectively)		68,787			31,646
Additional paid-in capital		90,089			75,715
Accumulated deficit		(108,185)			(90,983)
Total shareholders' equity		50,691			16,378
Total liabilities and shareholders' equity	$	55,659	$		19,638

 

 

 

CHECK CAP LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except per share data)
	Twelve months ended December 31,									Three months ended December 31,
	2020				2021							2020					2021
Research and development expenses, net	$	12,349		$		10,008					$		4,126		$	2,831
General and administrative expenses		4,972				3,924							1,452			1,102
Operating loss		17,321				13,932							5,578			3,933
Finance Income, net		119				86							101			24
Net loss for the period	$	17,202		$		13,846					$		5,477		$	3,909
Loss per share:
Net loss per ordinary share basic and diluted		0.21				0.46							0.06			0.08
Weighted average number of ordinary shares outstanding - basic and diluted		82,807,556				30,351,368							96,408,753			46,236,425

 

 

 

	CHECK-CAP LTD.
	CONSOLIDATED STATEMENTS OF CASH FLOWS
	(U.S. dollars in thousands)
		Year ended					Three months ended
		December 31,					December 31,
		2021		2020			2021			2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(17,202)	$	(13,846)		$	(5,477)	$		(3,909)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation		205		148			66			41
Share-based compensation		491		408			223			91
Financial expense, net		-		7			47			34
Changes in assets and liabilities items:
Decrease (increase) in prepaid and other current assets and non-current assets		(549)		106			270			-
Increase (decrease) in trade accounts payable, accruals and other current liabilities		362		(317)			119			(22)
Increase in employees and payroll accruals		451		409			414			303
Decrease in royalties provision		(22)		(28)			(46)			(34)
Net cash used in operating activities	$	(16,264)	$	(13,113)		$	(4,384)	$		(3,496)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(1,006)		(379)			(263)			(86)
Proceeds from (Investment in) short-term bank and other deposits		(15,000)		(10,072)			(8,300)			4,931
Net cash provided by (used in) investing activities	$	(16,006)	$	(10,451)		$	(8,563)	$		4,845
CASH FLOWS FROM FINANCING ACTIVITIES
Exercise of warrants into ordinary shares, net of issuance expenses		19,219		-			-			-
Issuance of ordinary shares in the registered direct offerings, net of issuance expenses		31,801		10,139			(207)			-
Options exercise		4		-			4			-
Issuance of ordinary shares and warrants in the Warrant Exercise Transaction, net of issuance expenses		-		8,712			-			-
Issuance of ordinary shares in the private placement, net of issuance expenses		-		4,731			-			-
Net cash provided by financing activities	$	51,024	$	23,582		$	(203)	$		-
Net increase (decrease) in cash, cash equivalents and restricted cash		18,754		18			(13,150)			1,349
Cash, cash equivalents and restricted cash at the beginning of the period		8,053		8,035			39,957			6,704
Cash, cash equivalents and restricted cash at the end of the period	$	26,807	$	8,053		$	26,807	$	8,053

 

 

 

View original content:https://www.prnewswire.com/news-releases/check-cap-reports-fourth-quarter-and-full-year-2021-financial-results-301519864.html

SOURCE Check-Cap Ltd.

FAQ

What are Check-Cap's recent financial results for Q4 2021?

Check-Cap reported a net loss of $5.5 million for Q4 2021, compared to a loss of $3.9 million in Q4 2020.

When does Check-Cap plan to start its U.S. pivotal study?

Check-Cap anticipates initiating the U.S. pivotal study for C-Scan in April 2022.

What is the cash position of Check-Cap as of December 31, 2021?

As of December 31, 2021, Check-Cap had cash and equivalents totaling $51.9 million.

What were the total research and development expenses for Check-Cap in 2021?

Research and development expenses for 2021 were $12.3 million, up from $10.0 million in 2020.

What is the significance of the FDA's Breakthrough Device Designation for Check-Cap?

The FDA's Breakthrough Device Designation enhances C-Scan's recognition as a patient-friendly screening option for colorectal cancer.